Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946891 | 0.93 | THRB (0.87) | THRBTHRA | |
| Mb07344 SCHEMBL282003 | 0.89 | THRB (1.00) | THRBTHRA | |
| Mb07344 SCHEMBL29378732 | 0.89 | THRB (1.00) | THRBTHRA | |
| SCHEMBL3160842 | 0.86 | THRB (0.85) | THRBTHRA | |
| SCHEMBL1458026 | 0.86 | THRB (0.77) | THRBTHRA | |
| SCHEMBL13703175 | 0.85 | THRB (0.83) | THRBTHRA | |
| SCHEMBL1458111 | 0.84 | THRB (0.74) | THRBTHRA | |
| SCHEMBL28770829 | 0.84 | THRB (0.81) | THRBTHRA | |
| SCHEMBL3157077 | 0.84 | THRB (0.81) | THRBTHRA | |
| SCHEMBL28786130 | 0.84 | THRB (0.76) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220016137-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11202789-B2 | Method of treating glycogen storage disease | VIKING THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2020117962-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | VIKING THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | VIKING THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20190343850-A1 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE | VIKING THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | THRB 7/4885THRA 8/4885 |
| US-20220016137-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | COL2A1, COL1A1, TGFBR2 | THRB 30/4885THRA 187/4885 |
| US-11707472-B2 | Compositions for the treatment of fibrosis | COL2A1, TGFBR2, COL1A1 | THRB 33/4885THRA 251/4885 |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | COL2A1, TGFBR2, COL1A1 | THRB 33/4885THRA 251/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | THRB 6/4885THRA 2/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | THRB 3/4885THRA 1/4885 |
| US-11202789-B2 | Method of treating glycogen storage disease | GYS2, GYS1, PYGL | THRB 7/4885THRA 9/4885 |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, LIPC | THRB 19/4885THRA 25/4885 |
| US-20190343850-A1 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE | GYS2, GYS1, PYGL | THRB 7/4885THRA 9/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRB 41/4885THRA 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.